AI Insight
Researchers from Adelaide University report that the increasing use of GLP-1 medications like Ozempic and Mounjaro is revealing previously underrecognized connections between obesity and eating disorders, two conditions traditionally treated separately in healthcare systems. The widespread adoption of these medications is prompting clinicians to reconsider treatment approaches and identify which patients may benefit from these drugs versus those who could be at increased risk of adverse outcomes.
Why it matters
This overlap has significant implications for clinical practice, as it suggests that treatment protocols may need to be redesigned to screen for eating disorder risk factors before prescribing GLP-1 medications for weight loss. Understanding the intersection between these conditions could improve patient safety and treatment outcomes for individuals seeking obesity care.
Understand the Science
Obesity and eating disorders have traditionally been treated as separate areas of health care—but the rapid rise of GLP-1 medicines is increasingly bringing the two together. Adelaide University researchers say the growing use of medicines such as Ozempic and Mounjaro is highlighting an underrecognized overlap between the conditions—and raising important questions about who could benefit and who may be at risk.
Source: GLP-1 meds prompt rethink of obesity and eating disorder care